{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002780","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.487489+00:00","generated_at":"2026-06-05T00:23:39.400710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Path Holdings FY2023 net loss $16.1M; cash drops to $1.1M from $10.4M","bullets":["Net loss $16.1M ($33.63 per share) vs $13.9M ($38.12 per share) in FY2022.","Cash at Dec 31, 2023: $1.1M, down from $10.4M a year earlier.","R&D expense rose to $11.6M from $9.2M on manufacturing and trial enrollment.","Completed first dose cohort in Phase 1/1b trial of BP1002 for AML and Phase 1 trial for lymphoma/CLL.","G&A fell to $4.2M from $4.7M; net cash used in ops $11.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002780","json":"https://secwatch.observer/filing/0001558370-24-002780.json","markdown":"https://secwatch.observer/filing/0001558370-24-002780.md","text":"https://secwatch.observer/filing/0001558370-24-002780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/0001558370-24-002780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/bpth-20240308x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:23:39.400710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3d5540cc1a7f626fd28507f85f6ad6e54c7abea","claim":"BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2023 results: net income $16.1 million, or $33.63 per share, EPS $33.63 per share.","evidence_excerpt":"The Company reported a net loss of $16.1 million, or $33.63 per share, for the year ended December 31, 2023, compared to a net loss of $13.9 million, or $38.12 per share, for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/0001558370-24-002780-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$16.1 million, or $33.63 per share"},{"label":"EPS","value":"$33.63 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}